knowledge -WSS

knowledge

author：Wikipedia 2025-08-20 09:41:35 - browse：185

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

Paul Marchetti, the head of insurer Elevance Health’s pharmacy benefit manager, has left the company amid a wave of consumer complaints about patients receiving incorrect medicines or being unable to get their prescriptions filled.

Elevance did not confirm Marchetti’s departure as the president of CarelonRx, but according to his Linkedin profile, he left the company in May.

Elevance, the second-largest commercial health insurer in the country by market share, uses its CarelonRx subsidiary to manage its pharmacy business. In online complaints, CarelonRx customers point toward January 1 as the date when issues with obtaining their prescriptions from the company began. The reported problems include safety issues like receiving other people’s medications or receiving medications they discontinued years ago.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： ASCO: AstraZeneca says CAR

hotspot

leisure time

WSS

Ionis drug prevents swelling attacks due to hereditary angioedema

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Ionis drug prevents swelling attacks due to hereditary angioedema

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Pig kidney works a record two months in donated body

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

How medical schools plan to diversify without affirmative action

Continuity nursing helped my family in our darkest PICU moments

How medical schools plan to diversify without affirmative action

Moonlake's readout produced a cash windfall. Risks remain

Letters to First Opinion on caregivers, digital health, and more

Medicare proposal to cover medical devices draws a mixed reaction

Intellia reports positive results for its CRISPR

Supreme Court strikes down use of affirmative action

Ultragenyx gene therapy for rare liver ailment succeeds in late

focus

A common UTI test for kids haunts adults as a traumatic 'nightmare'

PEPFAR is under serious threat — and so is global health

Food makers tried to stack nutrition panel with preferred experts

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

hotspot

leisure time

hotspot

hotspot